Ashvattha Therapeutics ("Ashvattha"), a clinical-stage company developing a nanomedicine therapeutic that traverses the blood-retinal barrier in areas of inflammation selectively targeting activated ...

Panelists discuss how successfully integrating subcutaneous (SubQ) therapies into oncology practice depends on comprehensive education, optimized workflows, transparent patient communication, and ...

Panelists discuss how the rapid adoption of subcutaneous (SubQ) oncology therapies creates challenges around clinical autonomy, infusion center sustainability, patient experience, and reimbursement ...

On Tuesday, Cardiol Therapeutics Inc. CRDL CRDL announced positive study results demonstrating that subcutaneously administered cannabidiol - the active pharmaceutical ingredient in Cardiol's novel ...

REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics ("Ashvattha"), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers ...

LACHEN, Switzerland--(BUSINESS WIRE)--Octapharma announced today that pre-clinical data for SubQ-8 were presented during a symposium at the recent World Federation of Hemophilia (WFH) 2018 World ...

Keytruda, a Merck cancer immunotherapy that has become the world’s top-selling medication, is administered as an intravenous infusion over the course of 30 minutes. The pharmaceutical giant now has ...

BLA submitted to U.S. FDA for subcutaneous formulation of daratumumab Submission based on data from Phase III COLUMBA and Phase II PLEIADES studies Copenhagen, Denmark; July 12, 2019 – Genmab A/S ...

BRIUMVI sets the standard for CD20 administration with efficient twice-yearly 1-hour infusions. BRIUMVI should remain competitive with subcutaneous formulations. Whether or not BTKIs erode the ...

Roche has taken the lead in the race to bring subcutaneous checkpoint inhibitors to market in the West, reporting phase 3 results that tee it up to file for approval in the U.S. and the EU. The ...